Editing 42 Genetics
The edit can be undone. Please check the comparison below to verify that this is what you want to do, and then publish the changes below to finish undoing the edit.
Latest revision | Your text | ||
Line 8: | Line 8: | ||
* Ever increasing quantum of Genomic data to be analysed by industry | * Ever increasing quantum of Genomic data to be analysed by industry | ||
== | ==Idea== | ||
<vimeo>515726155</vimeo> | <vimeo>515726155</vimeo> | ||
Line 20: | Line 20: | ||
The team have significant experience in building genetic software, and in February 2020, we completed a validation project with Cambridge University, hosting and processing 15,000 whole genomes and achieving a publication in Nature journal along with NIHR and Genomics England. | The team have significant experience in building genetic software, and in February 2020, we completed a validation project with Cambridge University, hosting and processing 15,000 whole genomes and achieving a publication in Nature journal along with NIHR and Genomics England. | ||
==Team | ==Team== | ||
'''The Board of Directors include:''' | '''The Board of Directors include:''' | ||
Line 43: | Line 43: | ||
Brendan is currently COO at MSD Partners. Prior to MSD, he spent 10 years working in portfolio management and operational hedge fund roles . He received his M.B.A. from Harvard Business School in 2002. | Brendan is currently COO at MSD Partners. Prior to MSD, he spent 10 years working in portfolio management and operational hedge fund roles . He received his M.B.A. from Harvard Business School in 2002. | ||
[[Category:Thesis]] | [[Category:Thesis]] | ||
[[Category:Equities]] | [[Category:Equities]] |